This sounds kind of odd. Why would fertility specialists use a drug intended to treat breast cancer patients to help couples conceive? To those in the field, the concept is nothing new. Clomiphene (Clomid) is a close relative of Tamoxifen, a drug used for years to prevent the recurrence of breast cancer. These drugs which block the action of the female hormone estrogen, cause hormone fluctuations that stimulate eggs to grow. Over the past decade, doctors have begun to use another breast cancer drug called Femara or Letrozole to treat couples in with infertility. Like tamoxifen, letrozole is used to prevent recurrence in breast cancer patients, and like clomiphene, it can also be used to stimulate ovulation (release of an egg). Until now, clomid has been the gold standard to help make women ovulate since it is relatively inexpensive and safe. Recently, however, a large study was published suggesting that letrazole may actually be more effective than clomiphene and result in fewer multiple births. Over time, it is likely that letrazole may replace clomiphene as a first line fertility drug.
This is one of the most common questions patients ask their fertility doctors and/ or their OBGYNs. Fortunately the short answer is no and this is backed up by large research studies. While their purpose may be to prevent pregnancy, the contraceptive effect of the pill wears off rather quickly. In some women the return to normal cycles and fertility can take a number of months, but usually there is not much of a delay. In other women, such as those with ovulation disorders such as PCOS, coming off the pill may actually increase the chances for conception. If your cycles have not regulated themselves 6 months after stopping the pill or they are becoming less regular over time after then and you’re trying to get pregnant, it’s probably not the pill, and it’s time to discuss this with your GYN or fertility specialist.
Apparently according to the NFL, it is. One of the players on the Indianapolis Colts was suspended after taking clomiphene, a fertility pill commonly used by Fertility Specialists, OBGYNs and Urologists to help women (and sometime men) coping with infertility. Even though he was using it to help his wife get pregnant, successfully I might add, the NFL considers Clomid a “performance enhancing drug.” Most patients who have taken clomiphene, and put up with some its side effects would likely take issue with that assessment.
One of the most common questions patients ask us when they are about to start fertility drugs, is are they are safe? This question comes up whether they are going to start pills (Clomid, Femara) or injectable fertility drugs (Follistim, Gonal-F, Bravelle, Menopur). Unfortunately, the answers are not always so clear cut as we would like. One of the major concerns women have is about cancer, and the cancer which more women seem to fear than any other is breast cancer. In the past there have been questions about whether fertility drugs increase the risk of breast cancer. A recent study may help to reassure anxious couples. The researchers followed fertility patients from multiple institutions and showed that women treated with fertility drugs, both oral and injectables had the same rates of breast cancer as those who were not. The only exception was women with who took clomid for over year, who did have a slightly higher rate of breast cancer, another good reason to be proactive and see a fertility specialist early on.
Most Reproductive Medicine specialists know that our overweight patients often need higher doses of fertility medications, whether that is pills (clomiphene or Femara), or injections (Follistim, Gonal-F, Bravelle or Menopur). When we do IVF cycles, we also add a medication to prevent ovulation such as Lupron, Ganirelix or Cetrotide, and for the most part, the doses are not adjusted based on a patients weight. It turns out that doctors in Colorado looked at one of these drugs, Cetrotide (Cetrorelix) and found that overweight women actually metabolize the drug faster, meaning that the currently used dosing may not be sufficient in these patients. So, what does that mean? If the cetrotide does not last in the system long enough, premature ovulation may occur, and your IVF cycle could be cancelled. It may mean that we need to use higher or more frequent dosing in heavier women.
The Wall Street Journal recently published an article on one of the hot topics in Reproductive Medicine, Minimal stimulation IVF, also known as “Mini-IVF.” This is IVF with very low doses of fertility drugs. It certainly sounds appealing, fewer drugs, fewer doctor visits, fewer side effects and less cost in order to have a baby. But, like most things in life, there is always a downside. Mini-IVF has significantly lower pregnancy rates than regular IVF. Does it work for some couples? Absolutely. Is the lower cost and hassle worth the lower chances for pregnancy? At this time, the jury is still out.
The Endocrine Society has issued new guidelines for the diagnosis of Polycystic Ovarian Syndrome (PCOS). These guidelines developed by a special task force are based in part on the Rotterdam criteria and were recently published in the Journal of Clinical Endocrinology and Metabolism.
Women are diagnosed with PCOS when they have 2 out of the 3 following conditions:
- Problems with ovulation such as irregular cycles
- Excess levels of male hormone levels on bloodwork or based on symptoms such as abnormal hair growth or loss, acne
- Large numbers of ovarian follicles or “cysts” on ultrasound
Additionally, doctors will need to rule other hormonal disorders that may mimic PCOS and are advised to screen for medical diseases such as diabetes and hypertension that are more common in women with PCOS. They also issued recommendations for treatment of infertility and irregular cycles in PCOS patients.